Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents

Cancer Control. 2022 Jan-Dec:29:10732748221074051. doi: 10.1177/10732748221074051.

Abstract

Introduction: The prototype DNA hypomethylating agents 5-azacytidine (5AC) and decitabine (DAC) are currently FDA-approved for treatment of blood and bone marrow disorders like myelodysplastic syndrome. 5AC and DAC are considered similar drugs and were shown to induce histone modifications that modulate gene expression. The aim of this study is to compare the effect of both drugs on histone acetylation and methylation at multiple histone amino acids residues.

Methods: Mass spectrometry was used to compare the effect of both drugs on 95 different histone posttranslational modifications (PTMs) in leukemia cells. ChIP-Seq analysis was used to compare the impact of both drugs on the genome-wide acetylation of the H3K9 mark using primary leukemia cells from six de-identified AML patients.

Results: Both DAC and 5AC induced histone PTMs in different histone isoforms like H1.4, H2A, H3, H3.1, and H4. Changes in both histone methylation and acetylation were observed with both drugs; however, there were distinct differences in the histone modifications induced by the two drugs. Since both drugs were shown to increase the activity of the HDAC SIRT6 previously, we tested the effect of 5AC on the acetylation of H3K9, the physiological substrate SIRT6, using ChIP-Seq analysis and compared it to the previously published DAC-induced changes. Significant H3K9 acetylation changes (P< .05) were detected at 925 genes after 5AC treatment vs only 182 genes after DAC treatment. Nevertheless, the gene set modified by 5AC was different from that modified by DAC with only ten similar genes modulated by both drugs.

Conclusion: Despite similarity in chemical structure and DNA hypomethylating activity, 5AC and DAC induced widely different histone PTMs and considering them interchangeable should be carefully evaluated. The mechanism of these histone PTM changes is not clear and may involve modulation of the activity or the expression of the enzymes inducing histone PTMs.

Keywords: 5-azacytidine; DNA methylation; H3K9 acetylation; decitabine; leukemia.

MeSH terms

  • Acetylation / drug effects*
  • Azacitidine / pharmacology*
  • Cell Line, Tumor
  • DNA Methylation / drug effects*
  • Decitabine / pharmacology*
  • Histones / drug effects*
  • Humans
  • Leukemia / drug therapy
  • Protein Processing, Post-Translational / drug effects

Substances

  • Histones
  • Decitabine
  • Azacitidine